Ribociclib (LEE011) Rollover Study for Continued Access

2016-10-18 02:08:21 | BioPortfolio


This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Continued Access to Study Treatment(s)




Not yet recruiting



Results (where available)

View Results


Published on BioPortfolio: 2016-10-18T02:08:21-0400

Clinical Trials [428 Associated Clinical Trials listed on BioPortfolio]

Micra Transcatheter Pacing System Continued Access Study Protocol

Medtronic is sponsoring the Micra Continued Access (CA) study to provide continued access to the Micra System while the marketing application is under review by the Food and Drug Administr...

Protocol for Continued Patient Access to Study Drug

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). ...

A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer

This is a Phase I study to assess the safety and MTD of paclitaxel + ribociclib (LEE011) in patients with Rb+, advanced breast cancer. Dose escalation will be performed using standard 3 + ...

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical be...

PubMed Articles [43483 Associated PubMed Articles listed on BioPortfolio]

Treatment interruption after 2-year antiretroviral treatment (ART) initiated during acute/early HIV in infancy: a randomized trial.

Treatment interruption (TI) has been safe and durable in some pediatric studies but none have compared TI to continued antiretroviral treatment (ART) following ART initiation in early HIV. The objecti...

Universal access to DOTS in Delhi Prisons: Where do we stand?

Universal access implies that all tuberculosis (TB) patients in the community should have access to early, good quality diagnosis and treatment services that are affordable and convenient to the patie...

Endovascular treatment of atherosclerotic iliac stenosis: local and systemic complications of the open brachial access.

The femoral access is the approach of reference for iliac angioplasty. In the current context of an early ambulation and a minimisation of in-hospital stay period, the brachial access seems to be an a...

Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.

This study assessed second-line continued use of cetuximab for treatment of unresectable metastatic colorectal cancer (mCRC) after disease progression during first-line cetuximab-based therapy. Consec...

Drug Test Results as a Predictor of Retention among Patients Using Buprenorphine in a Comprehensive Outpatient Treatment Program.

The study examined the relationship between continued nonmedical drug use and treatment retention for patients receiving buprenorphine maintenance treatment (BMT) in a comprehensive addiction treatmen...

Medical and Biotech [MESH] Definitions

A surgical specialty concerned with the study and treatment of disorders of the ear, nose, and throat.

Providing an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Compassionate use trials allow patients to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called expanded access trial.

Data collected during dental examination for the purpose of study, diagnosis, or treatment planning.

The study and treatment of human behavior problems utilizing principles derived from the behavioral, medical, and social science with emphasis on promotion of mental health.

Differences in access to or availability of facilities and services

More From BioPortfolio on "Ribociclib (LEE011) Rollover Study for Continued Access"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Searches Linking to this Trial